Entrada Therapeutics (TRDA) Return on Capital Employed (2021 - 2026)
Entrada Therapeutics (TRDA) posted quarterly Return on Capital Employed of 52.9% for Q1 2026, down 5374.0% year-over-year from 1.0% in Q1 2025, and down 24.19% quarter-over-quarter from 42.6% in Q4 2025.
Entrada Therapeutics (TRDA) Return on Capital Employed (2021 - 2026) Analysis & Trends
Entrada Therapeutics' Return on Capital Employed history runs 6 years deep, the most recent figure standing at 52.9% for Q1 2026.
- In Q1 2026, Return on Capital Employed fell 5374.0% year-over-year to 52.9%; the TTM figure through Mar 2026 stood at 52.9% (down 5374.0% YoY), while the FY2025 annual figure was 36.94%, down 4720.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 52.9%, down from 42.6% in the prior quarter.
- The five-year high for Return on Capital Employed was 20.29% in Q2 2024, with the low at 52.9% in Q1 2026.
- The 5-year median for Return on Capital Employed is 21.47% (2025), against an average of 17.07%.
- The sharpest annual moves came in 2024 and 2026: Return on Capital Employed soared 4491 bps in 2024, then tumbled 5374 bps in 2026.
- Entrada Therapeutics' Return on Capital Employed stood at 40.3% in 2022, then surged by 98 bps to 0.99% in 2023, then surged by 1045 bps to 9.38% in 2024, then sank by 554 bps to 42.6% in 2025, then declined by 24 bps to 52.9% in 2026.
- Business Quant data shows TRDA's Return on Capital Employed at 52.9% in Q1 2026, 42.6% in Q4 2025, and 29.88% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Entrada Therapeutics | 290.47 Mn | 290.47 Mn | - | -59.67% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -59.67% |
| Mar 31, 2026 | -52.90% |
| Dec 31, 2025 | -42.60% |
| Sep 30, 2025 | -29.88% |
| Jun 30, 2025 | -21.47% |
| Mar 31, 2025 | 0.84% |
| Dec 31, 2024 | 9.38% |
| Sep 30, 2024 | 11.61% |
| Jun 30, 2024 | 20.29% |
| Mar 31, 2024 | 7.51% |
| Dec 31, 2023 | -0.99% |
| Sep 30, 2023 | -10.38% |
| Jun 30, 2023 | -20.51% |
| Mar 31, 2023 | -37.41% |
| Dec 31, 2022 | -40.30% |
| Sep 30, 2022 | -34.19% |
| Jun 30, 2022 | -27.25% |
| Mar 31, 2022 | -21.93% |
| Dec 31, 2021 | -24.07% |